All In Biotech

NDA 220381 · Fresenius Kabi USA

Glycophos

Sodium Glycerophosphate · Intravenous

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Jul 29, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

27

6 Phase 3, 2 recruiting

FAERS reports

364

358 serious, 52 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 8, 2026.

Glycophos is indicated as a source of phosphorus in adults and pediatric patients 12 years and older as part of parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. Glycophos is a phosphorus replacement product indicated as a source of phosphorus in adults and pediatric patients 12 years and older as part of parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )

Mechanism: Sodium glycerophosphate, an organic phosphate salt, functions as a source of phosphorus. Phosphorus in the form of organic and inorganic phosphate has a variety of biochemical functions in all organs and tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis, and bone mineralization.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 29, 2026 Original approval · Type 2 - New Active Ingredient LetterLabel
2 products under this application
  • GLYCOPHOS · SODIUM GLYCEROPHOSPHATE 4.32GM/20ML (216MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • GLYCOPHOS · SODIUM GLYCEROPHOSPHATE 21.6GM/100ML (216MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Glycerophosphate" as an intervention, any sponsor and status, largest first.

All 27 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malaise47
  • pyrexia43
  • vomiting30
  • nausea29
  • chills26
  • dyspnoea26
  • body temperature increased19
  • death18
  • device related infection17
  • tremor17
  • diarrhoea16
  • abdominal pain15

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20122
201419
20157
201622
201723
201872
201940
202013
202119
202222
202332
202425
202513
202655

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.